Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    16-August-2000      
Issue 125 Next Update - 14:00 UTC 08:00 EST    17-August-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya



















Back To Vidyya Legal Battle Delays Approval Of Generic Form Of Important Cancer Drug

Bristol-Myers Squibb Battles To Hang On To Patent Protection For Taxol

Bristol-Myers Squibb engaged in a legal maneuver that is likely to delay the launch of a less expensive, generic form of Taxol, the world's top selling cancer drug.

The major pharmaceutical company, Bristol-Myers, has listed a new patent on Taxol in response to a court order in its patent infringement suit initiated by American BioScience Inc. This new listing with the Food and Drug Administration could delay the agency from granting final approval for Ivax Inc.'s generic version of Taxol for up to 2 years.

Taxol, which had $1.5 billion in sales last year, was expected to lose its patent protection later this year, opening the way for Miami-based Ivax Inc. to be the first generic drugmaker to produce a cheaper, copy cat version.

Analysts said New York-based Bristol-Myers is interested in doing anything to delay a generic Taxol from coming to market. Generics, which usually cost less than half the price of brand names, can erase about 80 percent of a brand's sales within two years.

On the news of the legal battle, shares of Bristol-Myers on Tuesday rose $1.875 to $52.50, and Ivax plunged $13 to $29.375. Bothe stocks are traded on the NYSE.


Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.